Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 92


P1.50: Long-Term Safety and Efficacy of Darbepoetin Alfa in Subjects With Advanced Stage NSCLC Receiving Multi-Cycle Chemotherapy: Track: Supportive Care and Others.

Gascón P, Nagarkar R, Šmakal M, Syrigos K, Barrios CH, Sánchez JC, Zhang L, Henry DH, Fleishman A, De Oliveira Brandao C.

J Thorac Oncol. 2016 Oct;11(10S):S214-S215. doi: 10.1016/j.jtho.2016.08.072. Epub 2016 Sep 22. No abstract available.


Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics.

Lipton A, Fizazi K, Stopeck AT, Henry DH, Smith MR, Shore N, Martin M, Vadhan-Raj S, Brown JE, Richardson GE, Saad F, Yardley DA, Zhou K, Balakumaran A, Braun A.

Eur J Cancer. 2016 Jan;53:75-83. doi: 10.1016/j.ejca.2015.09.011. Epub 2015 Dec 13.


Hypocalcaemia in patients with metastatic bone disease treated with denosumab.

Body JJ, Bone HG, de Boer RH, Stopeck A, Van Poznak C, Damião R, Fizazi K, Henry DH, Ibrahim T, Lipton A, Saad F, Shore N, Takano T, Shaywitz AJ, Wang H, Bracco OL, Braun A, Kostenuik PJ.

Eur J Cancer. 2015 Sep;51(13):1812-21. doi: 10.1016/j.ejca.2015.05.016. Epub 2015 Jun 17.


Interleukin 1 receptor-associated kinase 1 (IRAK1) mutation is a common, essential driver for Kaposi sarcoma herpesvirus lymphoma.

Yang D, Chen W, Xiong J, Sherrod CJ, Henry DH, Dittmer DP.

Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):E4762-8. doi: 10.1073/pnas.1405423111. Epub 2014 Oct 23. Erratum in: Proc Natl Acad Sci U S A. 2015 May 5;112(18):E2412.


Readmission rates due to venous thromboembolism in cancer patients after abdominopelvic surgery, a retrospective chart review.

White CK, Langholtz J, Burns ZT, Kruse S, Sallee K, Henry DH.

Support Care Cancer. 2015 Apr;23(4):993-9. doi: 10.1007/s00520-014-2448-0. Epub 2014 Sep 27.


Pharmacovigilance in practice: erythropoiesis-stimulating agents.

Hedenus M, Ludwig H, Henry DH, Gasal E.

Cancer Med. 2014 Oct;3(5):1416-29. doi: 10.1002/cam4.275. Epub 2014 Jun 3. Review.


A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.

Rudek MA, Moore PC, Mitsuyasu RT, Dezube BJ, Aboulafia D, Gerecitano J, Sullivan R, Cianfrocca ME, Henry DH, Ratner L, Haigentz M Jr, Dowlati A, Little RF, Ivy SP, Deeken JF.

Cancer. 2014 Apr 15;120(8):1194-202. doi: 10.1002/cncr.28554. Epub 2014 Jan 28.


Systemically circulating viral and tumor-derived microRNAs in KSHV-associated malignancies.

Chugh PE, Sin SH, Ozgur S, Henry DH, Menezes P, Griffith J, Eron JJ, Damania B, Dittmer DP.

PLoS Pathog. 2013;9(7):e1003484. doi: 10.1371/journal.ppat.1003484. Epub 2013 Jul 18.


Reply to Araki et al.

Lipton A, Fizazi K, Stopeck AT, Henry DH, Braun AH.

Eur J Cancer. 2013 Jun;49(9):2266-8. doi: 10.1016/j.ejca.2013.02.037. Epub 2013 Apr 8. No abstract available.


Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047.

Levine AM, Noy A, Lee JY, Tam W, Ramos JC, Henry DH, Parekh S, Reid EG, Mitsuyasu R, Cooley T, Dezube BJ, Ratner L, Cesarman E, Tulpule A.

J Clin Oncol. 2013 Jan 1;31(1):58-64. doi: 10.1200/JCO.2012.42.4648. Epub 2012 Nov 19.


Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.

Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, Solal-Celigny P, Rodriguez G, Krzakowski M, Mehta ND, Lipton L, García-Sáenz JA, Pereira JR, Prabhash K, Ciuleanu TE, Kanarev V, Wang H, Balakumaran A, Jacobs I.

J Thorac Oncol. 2012 Dec;7(12):1823-9. doi: 10.1097/JTO.0b013e31826aec2b.


The assessment of thrombotic risk using a predictive model in metastatic cancer patients undergoing first-line therapy.

Kim SY, Burns ZT, Henry DH.

Thromb Res. 2012 Dec;130(6):967-70. doi: 10.1016/j.thromres.2012.09.008. Epub 2012 Oct 1. No abstract available.


Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S.

Eur J Cancer. 2012 Nov;48(16):3082-92. doi: 10.1016/j.ejca.2012.08.002. Epub 2012 Sep 10.


Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid.

Vadhan-Raj S, von Moos R, Fallowfield LJ, Patrick DL, Goldwasser F, Cleeland CS, Henry DH, Novello S, Hungria V, Qian Y, Feng A, Yeh H, Chung K.

Ann Oncol. 2012 Dec;23(12):3045-51. doi: 10.1093/annonc/mds175.


Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium.

Bayraktar UD, Ramos JC, Petrich A, Gupta N, Lensing S, Moore PC, Reid EG, Aboulafia DM, Ratner L, Mitsuyasu R, Cooley T, Henry DH, Barr P, Noy A.

Leuk Lymphoma. 2012 Dec;53(12):2383-9. doi: 10.3109/10428194.2012.697559. Epub 2012 Jul 9.


Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review.

Henry DH, Langer CJ, McKenzie RS, Piech CT, Senbetta M, Schulman KL, Stepanski EJ.

Support Care Cancer. 2012 Sep;20(9):2089-96. doi: 10.1007/s00520-011-1318-2. Epub 2011 Dec 11.


Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carrière P, Dansey R.

Ann Oncol. 2012 May;23(5):1341-7. doi: 10.1093/annonc/mdr435.


Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H.

J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22.


Parenteral iron therapy in cancer-associated anemia.

Henry DH.

Hematology Am Soc Hematol Educ Program. 2010;2010:351-6. doi: 10.1182/asheducation-2010.1.351.

Items per page

Supplemental Content

Loading ...
Support Center